{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-027974","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.526917+00:00","generated_at":"2026-06-14T01:03:12.836377+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"KalVista amends CFO employment agreement raising base salary to $565K; updates bylaws for universal proxy rules","bullets":["CFO Benjamin L. Palleiko's base salary raised to $565,000 (effective May 1, 2023); target bonus increased to 50% of salary.","Severance: 15 months base salary and COBRA if terminated without cause/for good reason before Change in Control.","If terminated within 2 years after Change in Control: 21 months base salary, full target bonus, full equity vesting, COBRA.","Bylaws amended for DGCL updates, universal proxy rules, and exclusive forum (Delaware Chancery Court)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-027974","json":"https://secwatch.observer/filing/0000950170-23-027974.json","markdown":"https://secwatch.observer/filing/0000950170-23-027974.md","text":"https://secwatch.observer/filing/0000950170-23-027974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/0000950170-23-027974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/kalv-20230608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:03:12.836377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc48fd9cf9a4676d0d89c2cec0975d671429d9ab","claim":"KalVista Pharmaceuticals, Inc.: Adopted amended and restated bylaws effective June 14, 2023, incorporating changes related to universal proxy rules, recent DGCL amendments, and other governance updates (effective 2023-06-14).","evidence_excerpt":"On June 14, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of KalVista Pharmaceuticals, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/0000950170-23-027974-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-06-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}